Supply Issue – Ramipril (Tryzan) Supply Disruption and Section 29A Alternatives

We are writing to advise you of a supply disruption affecting all strengths of Ramipril (Tryzan) due to an issue at the manufacturing site. Stock of the registered capsules is expected to run out progressively from late April through June, and no resupply of the registered product is expected until mid–late 2026.

To maintain continuity of treatment, the supplier has sourced alternatives for all strengths. The alternatives products are tablets rather than capsules, and are not Medsafe approved.

Key Information for Prescribers:

• All strengths of Ramipril (Tryzan) are affected by this supply disruption.

• Registered stock is expected to run out between late April and early June.

• Section 29A alternative tablets have been sourced for all strengths.

• Alternatives for 1.25 mg, 5 mg, and 10 mg will be listed on the Pharmaceutical Schedule from 1 May 2026.

• The 2.5 mg alternative is anticipated to be listed 1 June 2026.

• As these alternatives are not Medsafe approved, they must be prescribed and supplied in line with Section 29 of the Medicines Act.

Availability of the Section 29 alternatives will begin as registered stock runs through, with most strengths expected to transition in May.

We appreciate your support in managing this transition and ensuring patients continue to receive appropriate treatment. Further updates will be provided on our website as information becomes available – Ramipril (all strengths): Supply issue

Please share this information:

Please share this information with your colleagues and within your networks.

If you have any questions regarding this supply issue, please contact enquiry@pharmac.govt.nz.

Ngā mihi

Dr David Hughes